Oncotelic Therapeutics, Inc. (OTLC)

OTCMKTS · Delayed Price · Currency is USD
0.0464
+0.0005 (1.20%)
At close: Feb 27, 2026
Market Cap20.49M +67.7%
Revenue (ttm)n/a
Net Income-1.67M
EPS-0.00
Shares Out441.58M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume252,844
Average Volume388,841
Open0.0480
Previous Close0.0459
Day's Range0.0440 - 0.0490
52-Week Range0.0150 - 0.1100
Beta-0.64
RSI31.92
Earnings DateApr 13, 2026

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications. It develops antisense and small molecule injectable drugs for the treatment of cancer. The company is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-β2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute resp... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Vuong Trieu
Employees 26
Stock Exchange OTCMKTS
Ticker Symbol OTLC
Full Company Profile

Financial Performance

Financial Statements